YOUR SEARCH FOR Text 184 RESULTS
51 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… … Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance …
52 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs …
53 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs …
54 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs …
55 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… … Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance …
56 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs …
57 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
… … Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs …
58 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… … Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida …
59 of Total
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Offi
… … Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Offi …
60 of Total
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with
… Press Release View all news Incyte Announces Additional FDA Approval of … of age and older whose disease is not well controlled with topical prescription therapies, …